232 related articles for article (PubMed ID: 30092835)
1. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
[TBL] [Abstract][Full Text] [Related]
2. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.
Doyle HA; Koski RA; Bonafé N; Bruck RA; Tagliatela SM; Gee RJ; Mamula MJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1559-1569. PubMed ID: 30056598
[TBL] [Abstract][Full Text] [Related]
4. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
6. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
7. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
[TBL] [Abstract][Full Text] [Related]
8. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
9. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
10. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
12. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
13. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
Mu Z; Klinowska T; Dong X; Foster E; Womack C; Fernandez SV; Cristofanilli M
J Exp Clin Cancer Res; 2014 May; 33(1):47. PubMed ID: 24886365
[TBL] [Abstract][Full Text] [Related]
14. Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
Verma N; Müller AK; Kothari C; Panayotopoulou E; Kedan A; Selitrennik M; Mills GB; Nguyen LK; Shin S; Karn T; Holtrich U; Lev S
Cancer Res; 2017 Jan; 77(1):86-99. PubMed ID: 27793840
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
Rabia E; Garambois V; Hubert J; Bruciamacchie M; Pirot N; Delpech H; Broyon M; Theillet C; Colombo PE; Vie N; Tosi D; Gongora C; Khellaf L; Jarlier M; Radosevic-Robin N; Chardès T; Pèlegrin A; Larbouret C
MAbs; 2021; 13(1):1914883. PubMed ID: 33876707
[TBL] [Abstract][Full Text] [Related]
16. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
17. Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
Ren XR; Wei J; Lei G; Wang J; Lu J; Xia W; Spector N; Barak LS; Clay TM; Osada T; Hamilton E; Blackwell K; Hobeika AC; Morse MA; Lyerly HK; Chen W
Breast Cancer Res; 2012 Jun; 14(3):R89. PubMed ID: 22676470
[TBL] [Abstract][Full Text] [Related]
18. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
19. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL
Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797
[TBL] [Abstract][Full Text] [Related]
20. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]